NCT07519772 is a Phase 1, PHASE2 clinical trial of MK-1045 in Lymphoma, Non-Hodgkin, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT07519772?

NCT07519772 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT07519772?

Interventions in NCT07519772: MK-1045.

What condition does NCT07519772 study?

NCT07519772 studies Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse.

Is NCT07519772 still recruiting?

NCT07519772 is currently not yet recruiting. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07519772

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Not yet recruiting Phase 1, PHASE2 Last updated 9 April 2026

What this trial tests

Phase 1, PHASE2 trial testing MK-1045 in Lymphoma, Non-Hodgkin in 200 participants. Not yet recruiting.

Timeline

7 May 2026

Primary endpoint
20 January 2030

21 October 2030

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	7 May 2026
Primary completion	20 January 2030
Estimated completion	21 October 2030

Drugs / interventions tested

MK-1045 — full drug profile →

Conditions studied

Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
Lymphoma, Follicular — all drugs for Lymphoma, Follicular →
Lymphoma, Large B-Cell, Diffuse — all drugs for Lymphoma, Large B-Cell, Diffuse →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Lymphoma, Non-Hodgkin or Lymphoma, Follicular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MK-1045

Trials testing the same drug.

NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT05579132 — A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) · Phase 1, PHASE2 · recruiting
NCT06189391 — A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001 · Phase 1 · recruiting

Other recruiting trials for Lymphoma, Non-Hodgkin

Currently open trials in the same condition.

NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07519772 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07519772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing